Natrogen grants Takeda rights to Natura-alpha

Natrogen Therapeutics Intl. Inc. (New York, N.Y.) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) exclusive, worldwide rights to develop and commercialize Natura-alpha, which is in Phase II development to treat ulcerative colitis (UC). Takeda also received an exclusive option to acquire Natrogen for an undisclosed amount. Natrogen will receive an undisclosed upfront payment and is eligible for undisclosed regulatory and sales milestones. The company is also eligible for an undisclosed option exercise fee. ...